Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from InnoCare Pharma Ltd. ( (HK:9969) ) is now available.
InnoCare Pharma said it expects a sharp improvement in its 2025 financial performance, projecting operating revenue of about RMB2.37 billion, up roughly 134% from 2024, driven by rapid growth in drug sales, including a new first-line indication approval in April 2025 for its BTK inhibitor orelabrutinib to treat adult chronic lymphocytic leukemia and small lymphocytic lymphoma. The company anticipates turning profitable for the first time, with estimated net profit attributable to shareholders of around RMB633 million versus a RMB441 million loss in 2024, and net profit excluding non-recurring items of about RMB534 million compared with a RMB440 million loss a year earlier, marking a significant turnaround that underscores accelerating commercialization and could strengthen its competitive position in the oncology drug market.
The most recent analyst rating on (HK:9969) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.
More about InnoCare Pharma Ltd.
InnoCare Pharma Limited is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, with a portfolio that includes orelabrutinib and other targeted therapies. Listed in Hong Kong, the group operates primarily in the Chinese market, concentrating on treatments for oncology and autoimmune diseases and aiming to scale its commercial footprint as its drug revenues expand.
Average Trading Volume: 6,574,578
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.47B
Learn more about 9969 stock on TipRanks’ Stock Analysis page.